Evaluate and compare clinical parameters and patient reported outcomes of patients with secondary progressive multiple sclerosis (SPMS) to patients with relapsing remitting multiple sclerosis (RRMS) at high risk to develop SPMS to:

• - characterize patients in the transition from RRMS to SPMS
• - characterize differences in disease evolution
• - evaluate longitudinal performance of the progression questionnaire (MSProDiscuss) in clinical routine

Until today, the diagnosis of SPMS and especially identification of the transitional phase from RRMS to SPMS remains challenging as reliable clinical diagnostic criteria and tools are missing or not yet established.

In the prospective non-interventional study PANGAEA 2.0 EVOLUTION approximately 600 patients with either SPMS or RRMS at high risk for SPMS are followed independently of treatment for up to 2 years. As there are no standard criteria for the transition state from RRMS to SPMS, physicians independently assign patients to the ‘high risk for SPMS’ cohort after a comprehensive evaluation of the patient's symptoms according to their daily practice. At 6-month intervals routine clinical measurements, quality of life, socioeconomic parameters and MSProDiscuss outcomes are documented.  

Real world characteristics of approximately 600 patients will be shown including the first 12-month follow up findings of approximately 200 patients. Different progression profiles are analyzed to better characterize the transition phase of RRMS to SPMS including clinical, patient reported and quality of life outcomes. For the first time longitudinal data of the progression questionnaire MSProDiscuss is analyzed in real-world showing the impact of changes in the patient profile.

PANGAEA2.0 EVOLUTION allows comparing SPMS patient profiles to RRMS patients at risk for SPMS in a real world, yet well-structured setting. Combining clinical and non-clinical parameters for a patient profile may help to establish standard early diagnosis criteria and therapy of SPMS patients.